COL18A1 and non-small cell lung carcinoma: There were statistically significant differences in median PFS and OS between the 2 arms (P = 0.023 for median PFS and P < 0.001 for median OS, respectively), indicating that extended use of PT-DC plus endostatin resulted in a substantial survival advantage for NSCLC patients (HR = 0.67 [95% confidence interval = 0.48–0.95] for PFS, and HR = 0.45 [0.30–0.67] for OS).